Free Trial

Immatics Q3 2023 Earnings Report

Immatics logo
$6.85 -0.03 (-0.44%)
(As of 12/20/2024 05:16 PM ET)

Immatics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Immatics Revenue Results

Actual Revenue
$6.45 million
Expected Revenue
$11.05 million
Beat/Miss
Missed by -$4.60 million
YoY Revenue Growth
N/A

Immatics Announcement Details

Quarter
Q3 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Immatics Earnings Headlines

Mizuho Securities Sticks to Its Buy Rating for Immatics (IMTX)
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Immatics moved to Buy from Not Rated at Goldman Sachs
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
See More Immatics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email.

About Immatics

Immatics (NASDAQ:IMTX) N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

View Immatics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings